MaxCyte

MaxCyte Net Debt

The Net Debt of MaxCyte (MXCT) as of Sep 27, 2026 is -85.10 M USD. In the previous year, Net Debt was -136.45 M USD — a change of -37.63% (higher).

Net Debt

-85.10 MUSD

YoY

-37.63%

Last updated:

Net Debt of MaxCyte is 2026 -85.10 M USD. Net Debt of MaxCyte was 2025 -136.45 M USD. It decreases by -37.63% higher compared to the previous year.

The MaxCyte Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-9.38 M USD
Jan 1, 2019
-9.50 M USD
Jan 1, 2020
-27.80 M USD
Jan 1, 2021
-249.36 M USD
Jan 1, 2022
-211.25 M USD
Jan 1, 2023
-149.55 M USD
Jan 1, 2024
-136.45 M USD
Jan 1, 2025
-85.10 M USD
The MaxCyte Net Debt history
YEARNet DebtYoY
-85.10 MUSD-37.63%
-136.45 MUSD-8.76%
-149.55 MUSD-29.21%
-211.25 MUSD-15.29%
-249.36 MUSD+797.10%
-27.80 MUSD+192.68%
-9.50 MUSD+1.22%
-9.38 MUSD-53.81%
-20.31 MUSD+202.23%
-6.72 MUSD-355.35%
2.63 MUSD+74.91%
1.50 MUSD—
Access this data via the Eulerpool API
Get Free API Key

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Net Debt of MaxCyte is -85.10 M USD in 2026.

Net Debt of MaxCyte changed from -136.45 M USD to -85.10 M USD, representing a -37.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt MaxCyte since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's MaxCyte historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — MaxCyte

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — MaxCyte